In patients with systemic sclerosis (SSc) treatmentrelated mortality after autologous stem cell transplantation (ASCT) appears to be increased as compared to patients with hematological malignancies. In our phase I/II study on ASCT in autoimmune diseases a patient with SSc died on day 2 after ASCT. Here we report the results of the autopsy which revealed advanced pulmonary and cardiac fibrosis as the most probable cause of death. In spite of detailed technical examination before enrollment, the cardiopulmonary function tests did not reflect the advanced stage of the disease. We conclude that in selected patients with SSc, biopsies should be performed to reduce mortality after ASCT. Bone Marrow Transplantation (2001) 27, 657-658. Keywords: systemic sclerosis; autologous stem cell transplantation; treatment-related mortality; histological findings Autologous stem cell transplantation (ASCT) is a novel experimental approach for treating patients with autoimmune diseases (AID) refractory to conventional therapy. To date, 275 patients with AID have been reported to the international registry of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT).
Summary:
In patients with systemic sclerosis (SSc) treatmentrelated mortality after autologous stem cell transplantation (ASCT) appears to be increased as compared to patients with hematological malignancies. In our phase I/II study on ASCT in autoimmune diseases a patient with SSc died on day 2 after ASCT. Here we report the results of the autopsy which revealed advanced pulmonary and cardiac fibrosis as the most probable cause of death. In spite of detailed technical examination before enrollment, the cardiopulmonary function tests did not reflect the advanced stage of the disease. We conclude that in selected patients with SSc, biopsies should be performed to reduce mortality after ASCT. Bone Marrow Transplantation (2001) 27, 657-658. Keywords: systemic sclerosis; autologous stem cell transplantation; treatment-related mortality; histological findings Autologous stem cell transplantation (ASCT) is a novel experimental approach for treating patients with autoimmune diseases (AID) refractory to conventional therapy. To date, 275 patients with AID have been reported to the international registry of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). 1 Particularly in patients with SSc, ASCT-related mortality appears to be increased as compared to patients with hematological malignancies. In the cohort of 41 patients with systemic sclerosis (SSc) with a median follow-up of 12 months (range, 3-55) the overall mortalitity was 27%. Seven out of 11 fatalities were reported as transplant-related (unpublished data). To date, three patients with SSc have been enrolled in our phase I/II study on ASCT in persist- ently active AID. 2 One of these three patients developed dyspnea, fluid retention and orthostatic hypotension during preparation with high-dose cyclophosphamide (CY) and antithymocyte globulin (ATG). In spite of vigorous supportive treatment she progressed to a fatal low-output state and died on day +2 after ASCT. A post-mortem examination was performed the following day.
Case report
The 46-year-old female patient with diffuse SSc was considered a candidate for ASCT in our phase I/II study for patients with persistently active AID because of the rapid progression of the disease without response to treatment. 2 Examinations before the onset of therapy disclosed no exclusion criteria of the EBMT/EULAR guidelines for blood and bone marrow stem cell transplants in autoimmune disease. 3 Pretransplant studies revealed the onset of lung fibrosis (HR-CT scan; lung function test: total lung capacity (TLC) 71.1%, residual volume (RV) in % of TLC 182%, transfer factor lung CO 2 (TLCO, steady state) 47.3%). Echocardiography (EF 60%), radionuclide ventriculography scan and myocardial perfusion imaging (no reduction of activity after pharmacological stress) showed normal results and no signs of pulmonary hypertension. The electrocardiogram demonstrated an intermittent tachyarrhythmia.
During the 32 days between the administration of cyclophosphamide (CY) 2 g/m 2 for stem cell mobilization and the onset of the immunoablative regimen further progression of the disease was observed. During and immediately following immunoablation with 200 mg CY/kg BW (days −5 to −2) and ATG 90 mg/kg BW (days −4 to −2) (rabbit; Fa. Fresenius, Bad Homburg, Germany) a dramatic weight gain of 7 kg (+17%) and pleural effusions were observed. During ATG treatment 500 mg methylprednisone were administered twice daily. In spite of intensive supportive treatment with diuretics and catecholamines, the patient developed a ventricular tachycardia with subsequent electro-mechanical uncoupling. Death occurred on day 2 after ASCT. The post-mortem histology (Figure 1b) revealed Figure 1 Myocardial damage due to CY-induced toxicity (a) vs cardiac involvement by systemic sclerosis (b). Myocardial damage is characterized by microangiopathy as indicated by diffuse interstitial hemorrhage and edema as described in an animal model by Kumar et al. 6 In contrast, cardiac involvement by systemic sclerosis is associated with diffuse interstitial fibrosis resulting in a collagenous encasement of individual muscle fibers (a, H&E; b, Masson's trichrome; scale bar, 60 m). cardiac fibrosis and no signs of CY-induced cardiotoxicity. The patient most probably died of right ventricular cardiac failure due to advanced pulmonary fibrosis (Figure 2 ) precipitated by the hyperhydration during preparative therapy. For comparison, Figure 1a shows the typical histological pattern of congestive heart failure due to cyclophosphamide-induced cardiomyopathy in a child after allogeneic BMT for severe aplastic anemia.
Discussion
Increased mortality after ASCT in patients with SSc as compared to other patients with AID has raised the question of whether these patients die due to transplant-related mortality 4, 5 or due to the progressive underlying disease. Obviously, in the patient discussed here the intensive examination before enrollment in the trial failed to detect the advanced cardiac and pulmonary fibrosis. Intermittent tachyarrhythmia as a sign of cardiac involvement does not generally herald increased mortality after ASCT as demonstrated in another patient with SSc and a patient with SLE who have also been included in our trial. 2 The other patient with SSc had an uneventful clinical course after ASCT and in the patient with SLE the tachyarrhythmia resolved completely. In the patient reported here who died after ASCT, a systemic inflammatory response syndrome, generally attributed to treatment with ATG, was prevented by high doses of methylprednisolone. Thus, induction of cardiac failure by ATG is unlikely.
In conclusion, in our patient we can exclude CY-induced cardiomyolysis as playing a significant pathogenetic role. The underlying disease (SSc) was shown to be the most probable cause of death which may have been precipitated by the hyperhydration during preparative therapy. Intensive investigation before enrollment did not detect the advanced cardiac and pulmonary fibrosis. Thus the patient did not fulfill any exclusion criterion. In selected patients, cardiac catheterization with myocardial and pulmonary biopsy may be necessary to avoid ASCT-associated mortality.
